The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Alphatec shares have added about 19.6% since the beginning of the year versus the S&P 500's decline of -5.3%. What's Next for Alphatec? Alphatec (ATEC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.34 per share a year ago. Th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52024 ALPHATEC HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-2463898 ( St ...

Alphatec (ATEC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and welcome to the webcast of ATEC's First Quarter Financial Results. We would like to remind everyone that participants on the call will make forward looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the SEC. During this call, you may hea ...

FORWARD LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not ...

Exhibit 99.1 ATEC Reports First Quarter 2025 Financial Results And Raises Full-Year Guidance Surgical revenue grew 24%; total revenue grew 22% Full-year revenue and profitability guidance increased Successfully refinanced convertible debt to 2030 maturity CARLSBAD, Calif., May 1, 2025 – Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2025, and recent corpor ...

Group 1 - The focus has shifted towards offshore drilling, supply industry, and shipping, including tankers, containers, and dry bulk [1] - The fuel cell industry is being monitored as it is still in its early stages of development [1] Group 2 - The individual has extensive experience in auditing with PricewaterhouseCoopers before transitioning to day trading nearly 20 years ago [2] - Successfully navigated significant market events such as the dotcom bubble, the aftermath of the World Trade Center attacks, and the subprime crisis [2]

Alphatec Holdings, Inc. (NASDAQ:ATEC) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Vik Chopra - Wells Fargo Eric Anderson - TD Cowen Phillip Dantoin - Piper Sandler Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Jason Wittes - ROTH David Saxon - Needham Kallum Titchmarsh - Morgan Stanley Operator Good afternoon, everyone, and welcome to the ...

Financial Performance - Total revenue for 2024 was $611.6 million, an increase of $129.3 million or 27% compared to $482.3 million in 2023[14] - Total revenue for the year ended December 31, 2024, was $611,562,000, an increase of $129,300,000 or 27% compared to $482,262,000 in 2023[209] - Cost of sales increased by $15,241,000 or 9% to $187,300,000 in 2024 from $172,059,000 in 2023, primarily due to increased product volume[211] - Research and development expenses rose by $10,603,000 or 15% to $80,718,000 in 2024, driven by increased personnel and stock-based compensation[212] - Sales, general and administrative expenses increased by $76,119,000 or 20% to $450,199,000 in 2024 compared to $374,080,000 in 2023[212] - Total operating expenses for 2024 were $560,431,000, an increase of $76,833,000 or 16% from $483,598,000 in 2023[212] - Litigation-related expenses decreased by $12,488,000 or 56% to $9,799,000 in 2024 from $22,287,000 in 2023[212] - Amortization expense increased by $1,974,000 or 14% to $16,258,000 in 2024 compared to $14,284,000 in 2023[212] - Transaction-related expenses significantly decreased by $1,903,000 or 90% to $210,000 in 2024 from $2,113,000 in 2023[212] - The company has experienced a 40% compound annual growth rate in revenue since its transformation began in 2018[199] - The company does not anticipate paying any cash dividends in the foreseeable future, intending to retain all available funds for business operations and expansion[184] Product Development and Innovation - Surgical volume grew by 19% in 2024, while average revenue per surgery expanded by 8% compared to 2023[24] - The surgeon user base increased by 18% in 2024, driven by the "ATEC Experience" educational program[26] - The company launched EOS Insight™ in 2024, a software platform designed to enhance spine patient care from pre-operative planning to post-operative assessment[18] - The acquisition of SafeOp™ technology has integrated real-time information about nerve health into surgical procedures, enhancing predictability and reproducibility[16] - The AIX™ product platform includes EOS imaging and SafeOp systems, with significant development expected to bring new functionalities to market in 2025 and beyond[36] - The PTP approach, launched in 2020, allows for single-position surgery, minimizing patient repositioning and enhancing surgical efficiency[34] - Invictus is a next-generation spinal fixation solution designed for various pathologies, emphasizing intraoperative adaptability and surgical predictability[44] - The company offers a range of biologics for spinal fusion, including 3D ProFuse™ Osteoconductive Bioscaffold and AlphaGRAFT® products, enhancing handling and endplate contact[45] - The research and development team is focused on reducing the time from product conceptualization to market commercialization, aiming to enhance clinical outcomes across multiple spine pathologies[47] Market and Competitive Landscape - The spinal implant industry is highly competitive, with significant competitors including Medtronic, Johnson & Johnson, and Stryker, which have greater financial resources and established distribution networks[60] - Continued consolidation in the healthcare industry may lead to increased competition and pricing pressures, adversely affecting the company's market position and financial condition[120] - The company faces intense competition from well-established medical device companies, which may hinder its ability to compete effectively[107] Regulatory and Compliance - The company’s products are subject to extensive FDA regulation, requiring either 510(k) clearance or PMA for commercial distribution in the U.S.[65] - The average FDA review time for 510(k) submissions is approximately six months, although the goal is to complete reviews within 90 days[73] - The PMA process is more complex and costly than the 510(k) process, requiring extensive data to demonstrate safety and effectiveness, with a typical review period of 180 days, often taking longer in practice[77] - Clinical trials are generally required for PMA applications and may also be needed for 510(k) submissions, with strict adherence to FDA regulations and oversight by Institutional Review Boards[78] - Compliance with FDA regulations post-market includes registration, quality system regulations, labeling, and advertising requirements, with potential enforcement actions for non-compliance[79][81] - The company must adhere to various federal and state laws regarding healthcare fraud and abuse, with significant penalties for violations, including exclusion from government healthcare programs[84][85] - The federal Anti-Kickback Statute prohibits remuneration for referrals related to federal healthcare programs, with broad interpretations that could impact various business arrangements[85] - The number of qui tam actions under the federal False Claims Act has increased, leading to more healthcare companies facing legal challenges, with potential penalties of up to three times the actual damages[88] - HIPAA regulations govern the use and disclosure of protected health information (PHI), impacting the company's access for marketing and research purposes[91] - The ACA includes provisions for increased enforcement against fraud and abuse, requiring disclosures of payments to physicians and teaching hospitals, with risks of fines for non-compliance[90] Human Resources and Workforce - As of December 31, 2024, the company had 867 employees worldwide, with 681 located in the U.S. and 186 outside the U.S.[97] - The company has experienced a low undesired turnover rate of approximately 5% for 2024, indicating high employee satisfaction and engagement[99] - The company employs a robust recruiting program to attract and retain a diverse workforce, which is crucial for its innovation in the medical device market[98] - The company has never experienced a work stoppage due to labor difficulties and maintains good relations with its employees[100] Financial Risks and Liabilities - The company has an accumulated deficit of $1.3 billion as of December 31, 2024, and has historically incurred net losses since inception[141] - The company may need to raise additional funds in the future, but such funds may not be available on acceptable terms, which could adversely affect its ability to repay debt or develop products[138] - The company’s financial results are subject to significant fluctuations due to factors such as product acceptance, demand, pricing, and regulatory approvals[143] - The company relies on its subsidiaries for cash flow, and any inability of these subsidiaries to provide dividends could impact the company's financial obligations[133] - Economic downturns or volatility could materially impact the company’s revenues and cash flows, particularly due to fixed costs associated with operations[142] - The company carries product liability insurance, but coverage may be inadequate, potentially harming financial condition if claims exceed limits[152] - The company is exposed to product liability claims related to biologics products, which may lead to significant legal fees and reputational harm[153] Strategic Initiatives and Future Outlook - The company aims to continue creating clinically distinct procedures to improve surgical outcomes and increase market share in the U.S. spine market[22] - The strategic initiatives focus on creating clinical distinction, compelling surgeon adoption, and elevating distribution to drive growth[22] - The company plans to pursue acquisitions of complementary businesses and technologies, but successful integration remains uncertain and could disrupt ongoing operations[126] - The effectiveness of the company's operations relies on its senior management and key personnel, with potential adverse effects on business if there are significant changes in these teams[128] Cybersecurity and Operational Risks - The company is vulnerable to cybersecurity threats, which could lead to data breaches and significant costs, impacting its reputation and financial condition[130] - Operations are conducted in areas at risk of natural disasters, which could cause substantial delays and financial losses, with insurance coverage potentially inadequate[131] Intellectual Property - As of December 31, 2024, the company owned or exclusively licensed 180 issued U.S. patents and 250 foreign patents, indicating a strong intellectual property position[63] - The company’s ability to protect its intellectual property is crucial, as inadequate protection could result in loss of market share to competitors[146] - The company is subject to potential patent litigation, which could incur substantial costs and divert management's attention from core business operations[148] Stockholder and Corporate Governance - As of February 19, 2025, executive officers, directors, and principal stockholders beneficially own approximately 30% of the outstanding common stock, allowing them to significantly influence corporate decisions[158] - As of February 19, 2025, there are approximately 425 holders of record for a total of 144,149,232 outstanding shares of common stock[183]

Preliminary Financial Information - Alphatec Holdings, Inc. announced preliminary unaudited financial information for the year ended December 31, 2024 [11] - The financial information is subject to adjustments and risks due to the ongoing closing process [11] - The press release containing the preliminary financial information is attached as Exhibit 99.1 [5][12] Stock Market Information - The company's common stock is traded on the Nasdaq Global Select Market under the symbol ATEC [8] Executive Signatory - The report was signed by J. Todd Koning, Executive Vice President and Chief Financial Officer, on January 13, 2025 [7]

Company Overview - Alphatec (ATEC) shares increased by 9.1% to $10.88 in the last trading session, with a higher-than-average trading volume, compared to a 3.6% gain over the past four weeks [1] - The company is part of the Zacks Medical - Instruments industry, which includes other companies like DexCom (DXCM) [4] Financial Performance - For the fourth quarter of 2024, Alphatec expects total revenue between $175.5 million and $177.0 million, while full-year 2024 revenue is projected to be between $610.3 million and $611.8 million, reflecting a 27% year-over-year increase [2] - The Zacks Consensus Estimate for fiscal 2024 revenue indicates a growth of 25.5% [2] - The upcoming quarterly report is anticipated to show a loss of $0.18 per share, which is a 51.4% year-over-year change, with revenues expected to be $170.5 million, up 23.6% from the previous year [3] Earnings Estimates - The consensus EPS estimate for Alphatec has been revised 19.2% lower over the last 30 days, which typically does not correlate with price appreciation [4] - The stock currently holds a Zacks Rank of 2 (Buy), indicating a positive outlook despite the recent downward revision in earnings estimates [4]